308 related articles for article (PubMed ID: 29940370)
1. α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.
Sainz V; Moura LIF; Peres C; Matos AI; Viana AS; Wagner AM; Vela Ramirez JE; S Barata T; Gaspar M; Brocchini S; Zloh M; Peppas NA; Satchi-Fainaro R; F Florindo H
Acta Biomater; 2018 Aug; 76():193-207. PubMed ID: 29940370
[TBL] [Abstract][Full Text] [Related]
2. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
3. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells.
Nakui M; Ohta A; Sekimoto M; Sato M; Iwakabe K; Yahata T; Kitamura H; Koda T; Kawano T; Makuuchi H; Taniguchi M; Nishimura T
Clin Exp Metastasis; 2000; 18(2):147-53. PubMed ID: 11235990
[TBL] [Abstract][Full Text] [Related]
5. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.
Mattarollo SR; Steegh K; Li M; Duret H; Foong Ngiow S; Smyth MJ
Immunol Cell Biol; 2013 Jan; 91(1):105-14. PubMed ID: 23090488
[TBL] [Abstract][Full Text] [Related]
6. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice.
Fujii S; Shimizu K; Hemmi H; Fukui M; Bonito AJ; Chen G; Franck RW; Tsuji M; Steinman RM
Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11252-7. PubMed ID: 16844772
[TBL] [Abstract][Full Text] [Related]
7. Role of γδ T cells in α-galactosylceramide-mediated immunity.
Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
[TBL] [Abstract][Full Text] [Related]
8. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice.
Shimizu K; Goto A; Fukui M; Taniguchi M; Fujii S
J Immunol; 2007 Mar; 178(5):2853-61. PubMed ID: 17312129
[TBL] [Abstract][Full Text] [Related]
9. Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity.
Fujii S; Goto A; Shimizu K
Blood; 2009 Apr; 113(18):4262-72. PubMed ID: 19164596
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.
Nakagawa R; Nagafune I; Tazunoki Y; Ehara H; Tomura H; Iijima R; Motoki K; Kamishohara M; Seki S
J Immunol; 2001 Jun; 166(11):6578-84. PubMed ID: 11359810
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with α-galactosylceramide and a Toll-like receptor agonist exerts an augmented suppressive effect on lung tumor metastasis in a mouse model.
Ando T; Ito H; Arioka Y; Ogiso H; Seishima M
Oncol Rep; 2015 Feb; 33(2):826-32. PubMed ID: 25434827
[TBL] [Abstract][Full Text] [Related]
12. Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells.
Verbeke R; Lentacker I; Breckpot K; Janssens J; Van Calenbergh S; De Smedt SC; Dewitte H
ACS Nano; 2019 Feb; 13(2):1655-1669. PubMed ID: 30742405
[TBL] [Abstract][Full Text] [Related]
13. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells.
Coelho-Dos-Reis JG; Huang J; Tsao T; Pereira FV; Funakoshi R; Nakajima H; Sugiyama H; Tsuji M
Clin Immunol; 2016 Jul; 168():6-15. PubMed ID: 27132023
[TBL] [Abstract][Full Text] [Related]
15. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.
Fujii S; Shimizu K; Kronenberg M; Steinman RM
Nat Immunol; 2002 Sep; 3(9):867-74. PubMed ID: 12154358
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
17. Regulation by Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 of alpha-galactosylceramide-induced antimetastatic activity and Th1 and Th2 responses of NKT cells.
Okajo J; Kaneko Y; Murata Y; Tomizawa T; Okuzawa C; Saito Y; Kaneko Y; Ishikawa-Sekigami T; Okazawa H; Ohnishi H; Matozaki T; Nojima Y
J Immunol; 2007 May; 178(10):6164-72. PubMed ID: 17475843
[TBL] [Abstract][Full Text] [Related]
18. Natural killer T cell activation increases iNOS
Paul S; Chhatar S; Mishra A; Lal G
J Immunother Cancer; 2019 Aug; 7(1):208. PubMed ID: 31387637
[TBL] [Abstract][Full Text] [Related]
19. Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18.
Nishio S; Yamada N; Ohyama H; Yamanegi K; Nakasho K; Hata M; Nakamura Y; Fukunaga S; Futani H; Yoshiya S; Ueda H; Taniguchi M; Okamura H; Terada N
Cancer Sci; 2008 Jan; 99(1):113-20. PubMed ID: 17949451
[TBL] [Abstract][Full Text] [Related]
20. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.
Gableh F; Saeidi M; Hemati S; Hamdi K; Soleimanjahi H; Gorji A; Ghaemi A
J Biomed Sci; 2016 Jan; 23():16. PubMed ID: 26811064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
